Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline

Clin Infect Dis. 2001 Dec 15;33(12):E135-6. doi: 10.1086/324589. Epub 2001 Nov 7.


Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use*
  • Candida / drug effects*
  • Candidiasis, Vulvovaginal / drug therapy*
  • Female
  • Humans
  • Premenstrual Syndrome / drug therapy*
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sertraline / pharmacology
  • Sertraline / therapeutic use*


  • Antifungal Agents
  • Serotonin Uptake Inhibitors
  • Sertraline